Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very positive. A massive market!
Now employee share ownership plans, very mature thinking from such a small co.
Looks good to me!
If we could have an increase in the SP please!
;-)
All today's trades are buys, not sells, I have bought 2k @ 2.53...must be a seller there
It's all good news. Heading in the right direction. A top 5 pharma paying upfront with the right to license is great. Built in (but not guaranteed) value route. The Inbrx news was good too, back in May.
Arecor collaborates with top global pharma company. The industry are clearly recognising the value Arecor bring to the table.
INBRX-101 (a candidate developed by Arecor) Phase 1 topline results showed a favourable safety profile and demonstrated potential to achieve normal functional Alpha-1 antitrypsin levels with monthly dosing in patients with Alpha-1 antitrypsin deficiency (AATD).
I think the work with the University of Virginia is highly relevant here since The Center for Diabetes Technology at the University of Virginia pioneered an FDA approved artificial pancreas system which automatically monitors and regulates blood glucose levels in Type 1 diabetes patients.
In case you missed our webinar with Arecor Therapeutics (AREC), the recording can be found on our YouTube channel: https://youtu.be/DW_9-yNzVaY
I think they are involved in chemotherapy medication. 2022 pending patent GB202118175D0 seems to relate to bendamustine (used in the treatment of chronic lymphocytic leukemia, multiple myeloma and non-Hodgkin's lymphoma).
We are hosting a webinar with Arecor Therapeutics plc (AREC) on 15 March 2022, which may be of interest to current shareholders or potential investors. Sarah Howell (Chief Executive Officer) will be presenting. You can register here: https://www.sharesoc.org/events/sharesoc-webinar-with-arecor-therapeutics-plc-arec15-march-2022/
Good spot! I had thought about generic lifescience supplier like ThermoFisher who wanted to be able to supply easier to use consumables, but that match looks very accurate.
It sounds like they are working with Illumnia. "Our partner's products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments, expanding our reach into new markets."
"Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments."
https://www.dailymail.co.uk/health/article-10224601/Is-Covid-trigger-tsunami-type-2-diabetes.html ... imagine on a worldwide basis
So Inhibrx gained $400m in market cap in 2 days on the basis of phase data from the Arecor formulation. Proof that Arecor have the potential to add big value to pharma.
Inhibrx is up 23% pre-market on NASDAQ on positive phase 1 data from Alpha-1 Antitrypsin Deficiency candidate INBRX-101. Inhibrx are licensing a novel enhanced formulation of INBRX-101 from Arecor. ++++++++
Thank you very much Awonda...I had missed the RNS.